1932

Abstract

Human papillomavirus (HPV) is a recently identified causative agent for a subset of head and neck cancers, primarily in the oropharynx, and is largely responsible for the rising worldwide incidence of oropharyngeal cancer (OPC). Patients with HPV-positive OPC have distinct risk factor profiles and generally have a better prognosis than patients with traditional, HPV-negative, head and neck cancer. Concurrent chemotherapy and radiation is a widely accepted primary treatment modality for many patients with HPV-positive OPC. However, recent advances in surgical modalities, including transoral laser and robotic surgery, have led to the reemergence of primary surgical treatment for HPV-positive patients. Clinical trials are under way to determine optimal treatment strategies for the growing subset of patients with HPV-positive OPC. Similarly, identifying those patients with HPV-positive cancer who are at risk for recurrence and poor survival is critical in order to tailor individual treatment regimens and avoid potential undertreatment.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-051914-021907
2016-01-14
2024-04-18
Loading full text...

Full text loading...

/deliver/fulltext/med/67/1/annurev-med-051914-021907.html?itemId=/content/journals/10.1146/annurev-med-051914-021907&mimeType=html&fmt=ahah

Literature Cited

  1. Bodily J, Laimins LA. 1.  2011. Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol. 19:33–39 [Google Scholar]
  2. Munoz N, Bosch FX, de Sanjose S. 2.  et al. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518–27 [Google Scholar]
  3. Gillison ML, Koch WM, Capone RB. 3.  et al. 2000. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl. Cancer Inst. 92:709–20 [Google Scholar]
  4. Maxwell JH, Kumar B, Feng FY. 4.  et al. 2010. HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans. Head Neck 32:562–67 [Google Scholar]
  5. Ryerson AB, Peters ES, Coughlin SS. 5.  et al. 2008. Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998–2003. Cancer 113:2901–9 [Google Scholar]
  6. Conway DI, Brenner DR, McMahon AD. 6.  et al. 2015. Estimating and explaining the effect of education and income on head and neck cancer risk: INHANCE consortium pooled analysis of 31 case-control studies from 27 countries. Int. J. Cancer 136:1125–39 [Google Scholar]
  7. Chaturvedi AK, Engels EA, Pfeiffer RM. 7.  et al. 2011. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol. 29:4294–301 [Google Scholar]
  8. Chenevert J, Chiosea S. 8.  2012. Incidence of human papillomavirus in oropharyngeal squamous cell carcinomas: now and 50 years ago. Hum. Pathol. 43:17–22 [Google Scholar]
  9. Maxwell JH, Ferris RL, Gooding W. 9.  et al. 2013. Extracapsular spread in head and neck carcinoma: impact of site and human papillomavirus status. Cancer 119:3302–8 [Google Scholar]
  10. Ang KK, Harris J, Wheeler R. 10.  et al. 2010. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363:24–35 [Google Scholar]
  11. Fakhry C, Westra WH, Li S. 11.  et al. 2008. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl. Cancer Inst. 100:261–69 [Google Scholar]
  12. D'Souza G, Kreimer AR, Viscidi R. 12.  et al. 2007. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 356:1944–56 [Google Scholar]
  13. Bajos N, Bozon M, Beltzer N. 13.  et al. 2010. Changes in sexual behaviours: from secular trends to public health policies. AIDS 24:1185–91 [Google Scholar]
  14. Turner CF, Danella RD, Rogers SM. 14.  1995. Sexual behavior in the United States 1930–1990: trends and methodological problems. Sex. Transm. Dis. 22:173–90 [Google Scholar]
  15. D'Souza G, Cullen K, Bowie J. 15.  et al. 2014. Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection. PLoS ONE 9:e86023 [Google Scholar]
  16. Thorland EC, Myers SL, Gostout BS, Smith DI. 16.  2003. Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene 22:1225–37 [Google Scholar]
  17. O'Brien PM, Saveria Campo M. 17.  2002. Evasion of host immunity directed by papillomavirus-encoded proteins. Virus Res. 88:103–17 [Google Scholar]
  18. Stanley MA, Pett MR, Coleman N. 18.  2007. HPV: from infection to cancer. Biochem. Soc. Trans. 35:1456–60 [Google Scholar]
  19. Kanodia S, Fahey LM, Kast WM. 19.  2007. Mechanisms used by human papillomaviruses to escape the host immune response. Curr. Cancer Drug Targets 7:79–89 [Google Scholar]
  20. Scott M, Nakagawa M, Moscicki AB. 20.  2001. Cell-mediated immune response to human papillomavirus infection. Clin. Diagn. Lab. Immunol. 8:209–20 [Google Scholar]
  21. Beachler DC, Viscidi R, Sugar EA. 21.  et al. 2015. A longitudinal study of human papillomavirus 16 L1, E6, and E7 seropositivity and oral human papillomavirus 16 infection. Sex. Transm. Dis. 42:93–97 [Google Scholar]
  22. Gillison ML, Broutian T, Pickard RK. 22.  et al. 2012. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA 307:693–703 [Google Scholar]
  23. Ragin CC, Taioli E. 23.  2007. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int. J. Cancer 121:1813–20 [Google Scholar]
  24. Parsons JT, Mendenhall WM, Stringer SP. 24.  et al. 2002. Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer 94:2967–80 [Google Scholar]
  25. Bourhis J, Overgaard J, Audry H. 25.  et al. 2006. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368:843–54 [Google Scholar]
  26. Forastiere AA, Zhang Q, Weber RS. 26.  et al. 2013. Long-term results of RTOG 91–11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J. Clin. Oncol. 31:845–52 [Google Scholar]
  27. Calais G, Alfonsi M, Bardet E. 27.  et al. 1999. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J. Natl. Cancer Inst. 91:2081–86 [Google Scholar]
  28. Fischer CA, Zlobec I, Green E. 28.  et al. 2010. Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of [sic] the treatment modality?. Int. J. Cancer 126:1256–62 [Google Scholar]
  29. Straetmans JM, Olthof N, Mooren JJ. 29.  et al. 2009. Human papillomavirus reduces the prognostic value of nodal involvement in tonsillar squamous cell carcinomas. Laryngoscope 119:1951–57 [Google Scholar]
  30. Ward MJ, Mellows T, Harris S. 30.  et al. 2015. Staging and treatment of oropharyngeal cancer in the human papillomavirus era. Head Neck 371002–13
  31. Spector ME, Gallagher KK, Bellile E. 31.  et al. 2014. Patterns of nodal metastasis and prognosis in human papillomavirus-positive oropharyngeal squamous cell carcinoma. Head Neck 36:1233–40 [Google Scholar]
  32. Strong MS, Jako GJ. 32.  1972. Laser surgery in the larynx. Early clinical experience with continuous CO2 laser. Ann. Otol. Rhinol. Laryngol. 81:791–98 [Google Scholar]
  33. Haughey BH, Hinni ML, Salassa JR. 33.  et al. 2011. Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck 33:1683–94 [Google Scholar]
  34. Grant DG, Hinni ML, Salassa JR. 34.  et al. 2009. Oropharyngeal cancer: a case for single modality treatment with transoral laser microsurgery. Otolaryngol.–Head Neck Surg. 135:1225–30 [Google Scholar]
  35. Huang K, Xia P, Chuang C. 35.  et al. 2008. Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: the University of California–San Francisco experience. Cancer 113:497–507 [Google Scholar]
  36. O'Malley BW Jr, Weinstein GS, Snyder W, Hockstein NG. 36.  2006. Transoral robotic surgery (TORS) for base of tongue neoplasms. Laryngoscope 116:1465–72 [Google Scholar]
  37. Weinstein GS, O'Malley BW Jr, Cohen MA, Quon H. 37.  2010. Transoral robotic surgery for advanced oropharyngeal carcinoma. Otolaryngol.–Head Neck Surg. 136:1079–85 [Google Scholar]
  38. Genden EM, Desai S, Sung CK. 38.  2009. Transoral robotic surgery for the management of head and neck cancer: a preliminary experience. Head Neck 31:283–89 [Google Scholar]
  39. Hurtuk A, Agrawal A, Old M. 39.  et al. 2011. Outcomes of transoral robotic surgery: a preliminary clinical experience. Otolaryngol.–Head Neck Surg. 145:248–53 [Google Scholar]
  40. Maxwell JH, Mehta V, Wang H. 40.  et al. 2014. Quality of life in head and neck cancer patients: impact of HPV and primary treatment modality. Laryngoscope 124:1592–97 [Google Scholar]
  41. Maxwell JH, Kumar B, Feng FY. 41.  et al. 2010. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin. Cancer Res. 16:1226–35 [Google Scholar]
  42. Holliday MA, Tavaluc R, Zhuang T. 42.  et al. 2013. Oncologic benefit of tonsillectomy in stage I and II tonsil cancer: a surveillance epidemiology and end results database review. Otolaryngol.–Head Neck Surg. 139:362–66 [Google Scholar]
  43. O'Sullivan B, Huang SH, Siu LL. 43.  et al. 2013. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J. Clin. Oncol. 31:543–50 [Google Scholar]
  44. Schiller JT, Castellsague X, Garland SM. 44.  2012. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30:Suppl. 5F123–38 [Google Scholar]
  45. Gildener-Leapman N, Lee J, Ferris RL. 45.  2014. Tailored immunotherapy for HPV positive head and neck squamous cell cancer. Oral Oncol. 50:780–84 [Google Scholar]
  46. Gildener-Leapman N, Ferris RL, Bauman JE. 46.  2013. Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol. 49:1089–96 [Google Scholar]
  47. Brun JL, Dalstein V, Leveque J. 47.  et al. 2011. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am. J. Obstet. Gynecol. 204:169.e1–169.e8 [Google Scholar]
  48. Sewell DA, Pan ZK, Paterson Y. 48.  2008. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine 26:5315–20 [Google Scholar]
  49. Quezada S, Peggs K. 49.  2013. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br. J. Cancer 108:1560–65 [Google Scholar]
  50. Lyford-Pike S, Peng S, Young G. 50.  et al. 2013. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 73:1733–41 [Google Scholar]
  51. Badoual C, Hans S, Merillon N. 51.  et al. 2013. PD-1-expressing tumor infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 73:128–38 [Google Scholar]
  52. 52. Cancer Genome Atlas Network 2015. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517:576–82 [Google Scholar]
  53. Seiwert TY, Zuo Z, Keck MK. 53.  et al. 2015. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin. Cancer Res. 21:632–41 [Google Scholar]
  54. Parfenov M, Pedamallu CS, Gehlenborg N. 54.  et al. 2014. Characterization of HPV and host genome interactions in primary head and neck cancers. PNAS 111:15544–49 [Google Scholar]
  55. Akagi K, Li J, Broutian TR. 55.  et al. 2014. Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res. 24:185–99 [Google Scholar]
  56. Ojesina AI, Lichtenstein L, Freeman SS. 56.  et al. 2014. Landscape of genomic alterations in cervical carcinomas. Nature 506:371–75 [Google Scholar]
  57. Rusan M, Li YY, Hammerman PS. 57.  2015. Genomic landscape of human papillomavirus-associated cancers. Clin. Cancer Res 21:2009–19 [Google Scholar]
/content/journals/10.1146/annurev-med-051914-021907
Loading
/content/journals/10.1146/annurev-med-051914-021907
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error